Show overview
The Readout Loud has been publishing since 2018, and across the 8 years since has built a catalogue of 419 episodes. That works out to roughly 210 hours of audio in total. Releases follow a weekly cadence.
Episodes typically run twenty to thirty-five minutes — most land between 26 min and 35 min — and the run-time is fairly consistent across the catalogue. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Business show.
The show is actively publishing — the most recent episode landed 3 days ago, with 33 episodes already out so far this year. Published by STAT.
From the publisher
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Latest Episodes
View all 419 episodesThe FDA's Overton era, and dispatches from Shanghai
Definium's new psychedelics data, and a reprieve for international scientists
Why two promising heart drugs flopped and what's next
411: Capricor's data clash and a fugitive in the C-suite
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
408: Whistleblower takes on health insurance and FDA commissioner candidates
407: The mysterious case of Eli Lilly's obesity drug
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
405: An obesity drug deep-dive, and peptides move mainstream
404: What RevMed's pancreatic cancer drug meant for one patient
403: Biotech exec Jeremy Levin on the industry's strategic turning point
402: Guarding biotech from China and big bets in longevity
401: Makary’s departure and Cassidy’s tenuous Senate seat
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
399: Hair-raising trial results, and Servier’s M&A wishlist
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
396: A new trick for old science, and biotech VCs' scrambled playbook
395: Biotech investors' plea to Trump, and a busy M&A week
How has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison go on her vacation? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's weekly biotech podcast. Biotech investor Rod Wong joins us to talk about why an industry-patient coalition he's part of sent a letter to President Trump asking for more regulatory flexibility at the FDA. We also discuss the U.S. approval of Eli Lilly's obesity pill, recent deal-making by large pharma companies, a strange story about promotion of psychedelic drugs on YouTube, and more.